{"id":"amoxicillin","rwe":[],"_fda":{"id":"a2a30785-599c-4436-a3cc-b4db011b7a87","set_id":"00cf4429-e37c-4490-b22d-3cd796124296","openfda":{"unii":["804826J2HU","Q42OMW3AT8"],"route":["ORAL"],"rxcui":["562508"],"spl_id":["a2a30785-599c-4436-a3cc-b4db011b7a87"],"brand_name":["AMOXICILLIN AND CLAVULANATE POTASSIUM"],"spl_set_id":["00cf4429-e37c-4490-b22d-3cd796124296"],"package_ndc":["50090-6324-0","50090-6324-3","50090-6324-1","50090-6324-2"],"product_ndc":["50090-6324"],"generic_name":["AMOXICILLIN AND CLAVULANATE POTASSIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AMOXICILLIN","CLAVULANATE POTASSIUM"],"manufacturer_name":["A-S Medication Solutions"],"application_number":["NDA050720"],"original_packager_product_ndc":["81964-221"]},"version":"4","pregnancy":["8.1 Pregnancy Teratogenic Effects : Pregnancy Category B. Reproduction studies performed in pregnant rats and mice given Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to Amoxicillin and Clavulanate Potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"overdosage":["10 OVERDOSAGE In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms 1 . Interstitial nephritis resulting in oliguric renal failure has been reported in patients after overdosage with amoxicillin and clavulanate potassium. Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin and clavulanate potassium overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin and clavulanate potassium crystalluria. Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin and clavulanate potassium. Amoxicillin and clavulanate potassium may be removed from circulation by hemodialysis [see Dosage and Administration ( 2.4 )] ."],"references":["15 REFERENCES Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66‑67."],"description":["11 DESCRIPTION Amoxicillin and Clavulanate Potassium is an oral antibacterial combination consisting of amoxicillin and the beta‑lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6‑aminopenicillanic acid. The amoxicillin molecular formula is C 16 H 19 N 3 O 5 S•3H 2 O, and the molecular weight is 419.46. Chemically, amoxicillin is (2 S ,5 R ,6 R )-6-[( R )-(-)-2-Amino-2-( p -hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus . It is a beta-lactam structurally related to the penicillins and possesses the ability to inactivate some beta‑lactamases by blocking the active sites of these enzymes. The clavulanate potassium molecular formula is C 8 H 8 KNO 5 , and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium ( Z )(2 R ,5 R )-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate and may be represented structurally as: Amoxicillin and Clavulanate Potassium Tablets: 250 mg/125 mg: Each tablet contains 250 mg of amoxicillin as the trihydrate, and 125 mg of clavulanic acid (equivalent to 149 mg of clavulanate potassium). 500 mg/125 mg: Each tablet contains 500 mg of amoxicillin as the trihydrate, and 125 mg of clavulanic acid (equivalent to 149 mg of clavulanate potassium). 875 mg/125 mg: Each tablet contains 875 mg of amoxicillin as the trihydrate, and 125 mg of clavulanic acid (equivalent to 149 mg of clavulanate potassium). Amoxicillin and Clavulanate Potassium for Oral Suspension: 125 mg/31.25 mg : Following constitution, each 5 mL of oral suspension contains 125 mg of amoxicillin as the trihydrate, and 31.25 mg of clavulanic acid (equivalent to 37.23 mg of clavulanate potassium). 200 mg/28.5 mg : Following constitution, each 5 mL of oral suspension contains 200 mg of amoxicillin as the trihydrate, and 28.5 mg of clavulanic acid (equivalent to 34 mg of clavulanate potassium). 250 mg/62.5 mg : Following constitution, each 5 mL of oral suspension contains 250 mg of amoxicillin as the trihydrate, and 62.5 mg of clavulanic acid (equivalent to 74.5 mg of clavulanate potassium). 400 mg/57 mg : Following constitution, each 5 mL of oral suspension contains 400 mg of amoxicillin as the trihydrate, and 57 mg of clavulanic acid (equivalent to 68 mg of clavulanate potassium). Amoxicillin and Clavulanate Potassium Chewable Tablets: 125 mg/31.25 mg: Each chewable tablet contains 125 mg of amoxicillin as the trihydrate, and 31.25 mg of clavulanic acid (equivalent to 37.23 mg of clavulanate potassium). 200 mg/28.5 mg: Each chewable tablet contains 200 mg of amoxicillin as the trihydrate, and 28.5 mg of clavulanic acid (equivalent to 34 mg of clavulanate potassium). 250 mg/62.5 mg: Each chewable tablet contains 250 mg of amoxicillin as the trihydrate, and 62.5 mg of clavulanic acid (equivalent to 74.5 mg of clavulanate potassium). 400 mg/57 mg: Each chewable tablet contains 400 mg of amoxicillin as the trihydrate, and 57 mg of clavulanic acid (equivalent to 68 mg of clavulanate potassium). Inactive Ingredients: Amoxicillin and Clavulanate Potassium Tablets - Colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide. • Each tablet of Amoxicillin and Clavulanate Potassium contains 0.63 mEq potassium. Amoxicillin and Clavulanate Potassium for Oral Suspension, 125 mg/31.5 mg per 5mL and 250 mg/62.5 mg per 5mL - Colloidal silicon dioxide, flavorings, xanthan gum, mannitol, succinic acid, silica gel and sodium saccharin. • Each 5 mL of reconstituted 125 mg/31.5 mg oral suspension of Amoxicillin and Clavulanate Potassium contains 0.16 mEq potassium • Each 5 mL of reconstituted 250 mg/62.5 mg oral suspension of Amoxicillin and Clavulanate Potassium contains 0.32 mEq potassium Amoxicillin and Clavulanate Potassium for Oral Suspension, 200 mg/28.5 mg per 5mL and 400 mg/57 mg per 5mL - Colloidal silicon dioxide, flavorings, xanthan gum, silica gel, hypromellose and aspartame [see Warnings and Precautions ( 5.7 )] • Each 5 mL of reconstituted 200 mg/28.5 mg oral suspension of Amoxicillin and Clavulanate Potassium contains 0.14 mEq potassium • Each 5 mL of reconstituted 400 mg/57 mg oral suspension of Amoxicillin and Clavulanate Potassium contains 0.29 mEq potassium Amoxicillin and Clavulanate Potassium Chewable Tablets, 125 mg/31.25 mg and 250 mg/62.5 mg - Colloidal silicon dioxide, flavorings, magnesium stearate, mannitol, sodium saccharin, glycine, and D&C Yellow No.10. Each 125 mg/31.25 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 0.16 mEq potassium Each 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 0.32 mEq potassium Amoxicillin and Clavulanate Potassium Chewable Tablets, 200 mg/28.5 mg and 400 mg/57 mg - Colloidal silicon dioxide, flavorings, magnesium stearate, mannitol, FD&C Red No. 40 and aspartame [see Warnings and Precautions ( 5.7 )] Each 200 mg/28.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 0.14 mEq potassium Each 400 mg/57 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 0.29 mEq potassium structure-amoxicillin structure-clav-acid"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Product: 50090-6324 NDC: 50090-6324-0 20 TABLET, COATED in a BOTTLE NDC: 50090-6324-1 10 TABLET, COATED in a BOTTLE NDC: 50090-6324-2 14 TABLET, COATED in a BOTTLE NDC: 50090-6324-3 28 TABLET, COATED in a BOTTLE"],"microbiology":["12.4 Microbiology Amoxicillin is a semisynthetic antibacterial with in vitro bactericidal activity against Gram-positive and Gram-negative bacteria. Amoxicillin is, however, susceptible to degradation by beta-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate some beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated beta-lactamases frequently responsible for transferred drug resistance. The formulation of amoxicillin and clavulanic acid in Amoxicillin and Clavulanate Potassium protects amoxicillin from degradation by some beta-lactamase enzymes and extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin. Amoxicillin and clavulanic acid has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections [see Indications and Usage ( 1 )] . Gram-positive bacteria Staphylococcus aureus Gram-negative bacteria Enterobacter species Escherichia coli Haemophilus influenzae Klebsiella species Moraxella catarrhalis The following in vitro data are available, but their clinical significance is unknown . At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for amoxicillin and clavulanic acid. However, the efficacy of amoxicillin and clavulanic acid in treating clinical infections due to these bacteria has not been established in adequate and well-controlled clinical trials. Gram-positive bacteria Enterococcus faecalis Staphylococcus epidermidis Staphylococcus saprophyticus Streptococcus pneumoniae Streptococcus pyogenes Viridans group Streptococcus Gram-negative Bacteria Eikenella corrodens Proteus mirabilis Anaerobic Bacteria Bacteroides species including Bacteroides fragilis Fusobacterium species Peptostreptococcus species Susceptibility Test Methods For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC ."],"geriatric_use":["8.5 Geriatric Use Of the 3,119 patients in an analysis of clinical studies of Amoxicillin and Clavulanate Potassium, 32% were greater than or equal to 65 years old, and 14% were greater than or equal to 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets have been established in pediatric patients. Use of Amoxicillin and Clavulanate Potassium in pediatric patients is supported by evidence from studies of Amoxicillin and Clavulanate Potassium Tablets in adults with additional data from a study of Amoxicillin and Clavulanate Potassium for Oral Suspension in pediatric patients aged 2 months to 12 years with acute otitis media [see Clinical Studies ( 14.2 )] . Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group. Dosing of Amoxicillin and Clavulanate Potassium should be modified in pediatric patients aged less than 12 weeks (less than 3 months) [see Dosage and Administration ( 2.3 )]."],"effective_time":"20240430","nursing_mothers":["8.3 Nursing Mothers Amoxicillin has been shown to be excreted in human milk. Amoxicillin and clavulanate potassium use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman."],"clinical_studies":["14 CLINICAL STUDIES 14.1 Lower Respiratory Tract and Complicated Urinary Tract Infections Data from 2 pivotal trials in 1,191 patients treated for either lower respiratory tract infections or complicated urinary tract infections compared a regimen of 875 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium every 12 hours to 500 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium dosed every 8 hours (584 and 607 patients, respectively). Comparable efficacy was demonstrated between the every 12 hours and every 8 hours dosing regimens. There was no significant difference in the percentage of adverse events in each group. The most frequently reported adverse event was diarrhea; incidence rates were similar for the 875 mg/125 mg every 12 hours and 500 mg/125 mg every 8 hours dosing regimens (15% and 14%, respectively); however, there was a statistically significant difference (p less than 0.05) in rates of severe diarrhea or withdrawals with diarrhea between the regimens: 1% for 875 mg/125 mg every 12 hours regimen versus 2% for the 500 mg/125 mg every 8 hours regimen. In one of these pivotal trials, patients with either pyelonephritis (n equals 361) or a complicated urinary tract infection (i.e., patients with abnormalities of the urinary tract that predispose to relapse of bacteriuria following eradication, n equals 268) were randomized (1:1) to receive either 875 mg/125mg tablets of Amoxicillin and Clavulanate Potassium every 12 hours (n equals 308) or 500 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium every 8 hours (n equals 321). The number of bacteriologically evaluable patients was comparable between the two dosing regimens. Amoxicillin and Clavulanate Potassium produced comparable bacteriological success rates in patients assessed 2 to 4 days immediately following end of therapy. The bacteriologic efficacy rates were comparable at one of the follow‑up visits (5 to 9 days post‑therapy) and at a late post‑therapy visit (in the majority of cases, this was 2 to 4 weeks post-therapy), as seen in Table 8. Table 8: Bacteriologic efficacy rates for Amoxicillin and Clavulanate Potassium Time Post Therapy 875 mg every 12 hours % (n) 500 mg every 8 hours % (n) 2 to 4 days 81% (58) 80% (54) 5 to 9 days 58% (41) 52% (52) 2 to 4 weeks 52% (101) 55% (104) As noted before, though there was no significant difference in the percentage of adverse events in each group, there was a statistically significant difference in rates of severe diarrhea or withdrawals with diarrhea between the regimens. 14.2 Acute Bacterial Otitis Media and Diarrhea in Pediatric Patients One US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of Amoxicillin and Clavulanate Potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of Amoxicillin and Clavulanate Potassium for 10 days in the treatment of acute otitis media. Only the suspension formulations were used in this trial. A total of 575 pediatric patients (aged 2 months to 12 years) were enrolled, with an even distribution among the 2 treatment groups and a comparable number of patients were evaluable (i.e., greater than or equal to 84%) per treatment group. Otitis media‑specific criteria were required for eligibility and a strong correlation was found at the end of therapy and follow‑up between these criteria and physician assessment of clinical response. The clinical efficacy rates at the end of therapy visit (defined as 2 to 4 days after the completion of therapy) and at the follow‑up visit (defined as 22 to 28 days post‑completion of therapy) were comparable for the 2 treatment groups, with the following cure rates obtained for the evaluable patients: At end of therapy, 87% (n equals 265) and 82% (n equals 260) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively. At follow‑up, 67% (n equals 249) and 69% (n equals 243) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively. Diarrhea was defined as either: (a) 3 or more watery or 4 or more loose/watery stools in 1 day; OR (b) 2 watery stools per day or 3 loose/watery stools per day for 2 consecutive days. The incidence of diarrhea was significantly lower in patients who received the every 12 hours regimen compared to patients who received the every 8 hours regimen (14% and 34%, respectively). In addition, the number of patients with either severe diarrhea or who were withdrawn with diarrhea was significantly lower in the every 12 hours treatment group (3% and 8% for the every 12 hours/10 day and every 8 hours/10 day, respectively). In the every 12 hours treatment group, 3 patients (1%) were withdrawn with an allergic reaction, while 1 patient in the every 8 hours group was withdrawn for this reason. The number of patients with a candidal infection of the diaper area was 4% and 6% for the every 12 hours and every 8 hours groups, respectively. It is not known if the finding of a statistically significant reduction in diarrhea with the oral suspensions dosed every 12 hours, versus suspensions dosed every 8 hours of Amoxicillin and Clavulanate Potassium, can be extrapolated to the chewable tablets. The presence of mannitol in the chewable tablets of Amoxicillin and Clavulanate Potassium may contribute to a different diarrhea profile. The every 12 hour oral suspensions (200 mg/28.5 mg per 5 mL and 400 mg/57 mg per 5 mL) are sweetened with aspartame."],"laboratory_tests":["7.5 Effects on Laboratory Tests High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST ® , Benedict's Solution, or Fehling's Solution. Since this effect may also occur with Amoxicillin and Clavulanate Potassium, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used. Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted."],"pharmacokinetics":["12.3 Pharmacokinetics Mean amoxicillin and clavulanate potassium pharmacokinetic parameters in normal adults following administration of Amoxicillin and Clavulanate Potassium Tablets are shown in Table 6 and following administration of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets are shown in Table 7. Table 6: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium Tablets a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5 hours after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose and Regimen of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 250 mg/125 mg every 8 hours 3.3 ± 1.12 1.5 ± 0.70 26.7 ± 4.56 12.6 ± 3.25 500 mg/125 mg every 12 hours 6.5 ± 1.41 1.8 ± 0.61 33.4 ± 6.76 8.6 ± 1.95 500 mg/125 mg every 8 hours 7.2 ± 2.26 2.4 ± 0.83 53.4 ± 8.87 15.7 ± 3.86 875 mg/125 mg every 12 hours 11.6 ± 2.78 2.2 ± 0.99 53.5 ± 12.31 10.2 ± 3.04 Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 400 mg/57 mg (5 mL of suspension) 6.94 ± 1.24 1.10 ± 0.42 17.29 ± 2.28 2.34 ± 0.94 400 mg/57 mg (1 chewable tablet) 6.67 ± 1.37 1.03 ± 0.33 17.24 ± 2.64 2.17 ± 0.73 Oral administration of 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or the equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg*h/mL for amoxicillin and 2.9 mcg*h/mL for clavulanic acid when 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium were administered to normal adults. One 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium or two 125 mg/31.25 mg chewable tablets of Amoxicillin and Clavulanate Potassium are equivalent to 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium and provide similar serum concentrations of amoxicillin and clavulanic acid. Amoxicillin serum concentrations achieved with Amoxicillin and Clavulanate Potassium are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. Time above the minimum inhibitory concentration of 1 mcg/mL for amoxicillin has been shown to be similar after corresponding every 12 hour and every 8-hour dosing regimens of Amoxicillin and Clavulanate Potassium in adults and children. Absorption : Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While Amoxicillin and Clavulanate Potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In one study, the relative bioavailability of clavulanate was reduced when Amoxicillin and Clavulanate Potassium was dosed at 30 and 150 minutes after the start of a high‑fat breakfast. Distribution : Neither component in Amoxicillin and Clavulanate Potassium is highly protein‑bound; clavulanic acid is approximately 25% bound to human serum and amoxicillin approximately 18% bound. Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. Two hours after oral administration of a single 35 mg/kg dose of suspension of Amoxicillin and Clavulanate Potassium to fasting children, average concentrations of 3 mcg/mL of amoxicillin and 0.5 mcg/mL of clavulanic acid were detected in middle ear effusions. Metabolism and Excretion: The half‑life of amoxicillin after the oral administration of Amoxicillin and Clavulanate Potassium is 1.3 hours and that of clavulanic acid is 1 hour. Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6 hours after administration of a single 250 mg/125 mg or 500 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium."],"adverse_reactions":["6 ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Anaphylactic reactions [see Warnings and Precautions (5.1) ] Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.2 )] Hepatic Dysfunction [see Warnings and Precautions (5.3) ] Clostridioides difficile Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4) ] The most frequently reported adverse effects were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact USAntibiotics, LLC at 1-844-454-5532 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported adverse reactions were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%). Less than 3% of patients discontinued therapy because of drug‑related adverse reactions. The overall incidence of adverse reactions, and in particular diarrhea, increased with the higher recommended dose. Other less frequently reported adverse reactions (less than 1%) include: Abdominal discomfort, flatulence, and headache. In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of Amoxicillin and Clavulanate Potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of Amoxicillin and Clavulanate Potassium for 10 days in the treatment of acute otitis media. A total of 575 patients were enrolled, and only the suspension formulations were used in this trial. Overall, the adverse reactions seen were comparable to that noted above; however, there were differences in the rates of diarrhea, skin rashes/urticaria, and diaper area rashes. [see Clinical Studies ( 14.2 )] . 6.2 Postmarketing Experience In addition to adverse reactions reported from clinical trials, the following have been identified during postmarketing use of Amoxicillin and Clavulanate Potassium. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to Amoxicillin and Clavulanate Potassium. Gastrointestinal: Indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. [see Warnings and Precautions ( 5.4 )] . Immune: Hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock), angioedema, serum sickness-like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia, and frequently fever), hypersensitivity vasculitis [see Warnings and Precautions ( 5.1 )] . Skin and Appendages: Rashes, pruritus, urticaria, erythema multiforme, SJS, TEN, DRESS, AGEP, exfoliative dermatitis [see Warnings and Precautions ( 5.2 )] . Liver: Hepatic dysfunction, including hepatitis and cholestatic jaundice, increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been reported with Amoxicillin and Clavulanate Potassium. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. Deaths have been reported [see Contraindications ( 4.2 ), Warnings and Precautions ( 5.3 )] . Renal: Interstitial nephritis, hematuria, and crystalluria have been reported [see Overdosage ( 10 )] . Hemic and Lymphatic Systems: Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Thrombocytosis was noted in less than 1% of the patients treated with Amoxicillin and Clavulanate Potassium. There have been reports of increased prothrombin time in patients receiving Amoxicillin and Clavulanate Potassium and anticoagulant therapy concomitantly [see Drug Interactions ( 7.2 )] . Central Nervous System: Agitation, anxiety, behavioral changes, aseptic meningitis, confusion, convulsions, dizziness, insomnia, and reversible hyperactivity have been reported. Miscellaneous: Tooth discoloration (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases."],"contraindications":["4 CONTRAINDICATIONS History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to Amoxicillin and Clavulanate Potassium or to other beta‑lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium. ( 4.2 ) 4.1 Serious Hypersensitivity Reactions Amoxicillin and Clavulanate Potassium is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin, clavulanate or to other beta‑lactam antibacterial drugs (e.g., penicillins and cephalosporins). 4.2 Cholestatic Jaundice/Hepatic Dysfunction Amoxicillin and Clavulanate Potassium is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium."],"drug_interactions":["7 DRUG INTERACTIONS Co‑administration with probenecid is not recommended. ( 7.1 ) Concomitant use of Amoxicillin and Clavulanate Potassium and oral anticoagulants may increase the prolongation of prothrombin time.( 7.2 ) Co-administration with allopurinol increases the risk of rash. ( 7.3 ) Amoxicillin and Clavulanate Potassium may reduce efficacy of oral contraceptives. ( 7.4 ) 7.1 Probenecid Probenecid decreases the renal tubular secretion of amoxicillin but does not delay renal excretion of clavulanic acid. Concurrent use with Amoxicillin and Clavulanate Potassium may result in increased and prolonged blood concentrations of amoxicillin. Co-administration of probenecid is not recommended. 7.2 Oral Anticoagulants Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently with Amoxicillin and Clavulanate Potassium. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation. 7.3 Allopurinol The concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients. 7.4 Oral Contraceptives Amoxicillin and Clavulanate Potassium may affect intestinal flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives. 7.5 Effects on Laboratory Tests High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST ® , Benedict's Solution, or Fehling's Solution. Since this effect may also occur with Amoxicillin and Clavulanate Potassium, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used. Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted."],"labor_and_delivery":["8.2 Labor and Delivery Oral ampicillin‑class antibacterials are poorly absorbed during labor. It is not known whether use of amoxicillin and clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention."],"mechanism_of_action":["12.1 Mechanism of Action Amoxicillin and Clavulanate Potassium is an antibacterial drug [see Microbiology ( 12.4 )] ."],"teratogenic_effects":["Teratogenic Effects : Pregnancy Category B. Reproduction studies performed in pregnant rats and mice given Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to Amoxicillin and Clavulanate Potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"recent_major_changes":["Warnings and Precautions ( 5 ) 8/2022"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Amoxicillin and Clavulanate Potassium is an antibacterial drug [see Microbiology ( 12.4 )] . 12.3 Pharmacokinetics Mean amoxicillin and clavulanate potassium pharmacokinetic parameters in normal adults following administration of Amoxicillin and Clavulanate Potassium Tablets are shown in Table 6 and following administration of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets are shown in Table 7. Table 6: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium Tablets a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5 hours after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose and Regimen of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 250 mg/125 mg every 8 hours 3.3 ± 1.12 1.5 ± 0.70 26.7 ± 4.56 12.6 ± 3.25 500 mg/125 mg every 12 hours 6.5 ± 1.41 1.8 ± 0.61 33.4 ± 6.76 8.6 ± 1.95 500 mg/125 mg every 8 hours 7.2 ± 2.26 2.4 ± 0.83 53.4 ± 8.87 15.7 ± 3.86 875 mg/125 mg every 12 hours 11.6 ± 2.78 2.2 ± 0.99 53.5 ± 12.31 10.2 ± 3.04 Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 400 mg/57 mg (5 mL of suspension) 6.94 ± 1.24 1.10 ± 0.42 17.29 ± 2.28 2.34 ± 0.94 400 mg/57 mg (1 chewable tablet) 6.67 ± 1.37 1.03 ± 0.33 17.24 ± 2.64 2.17 ± 0.73 Oral administration of 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or the equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg*h/mL for amoxicillin and 2.9 mcg*h/mL for clavulanic acid when 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium were administered to normal adults. One 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium or two 125 mg/31.25 mg chewable tablets of Amoxicillin and Clavulanate Potassium are equivalent to 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium and provide similar serum concentrations of amoxicillin and clavulanic acid. Amoxicillin serum concentrations achieved with Amoxicillin and Clavulanate Potassium are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. Time above the minimum inhibitory concentration of 1 mcg/mL for amoxicillin has been shown to be similar after corresponding every 12 hour and every 8-hour dosing regimens of Amoxicillin and Clavulanate Potassium in adults and children. Absorption : Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While Amoxicillin and Clavulanate Potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In one study, the relative bioavailability of clavulanate was reduced when Amoxicillin and Clavulanate Potassium was dosed at 30 and 150 minutes after the start of a high‑fat breakfast. Distribution : Neither component in Amoxicillin and Clavulanate Potassium is highly protein‑bound; clavulanic acid is approximately 25% bound to human serum and amoxicillin approximately 18% bound. Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. Two hours after oral administration of a single 35 mg/kg dose of suspension of Amoxicillin and Clavulanate Potassium to fasting children, average concentrations of 3 mcg/mL of amoxicillin and 0.5 mcg/mL of clavulanic acid were detected in middle ear effusions. Metabolism and Excretion: The half‑life of amoxicillin after the oral administration of Amoxicillin and Clavulanate Potassium is 1.3 hours and that of clavulanic acid is 1 hour. Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6 hours after administration of a single 250 mg/125 mg or 500 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium. 12.4 Microbiology Amoxicillin is a semisynthetic antibacterial with in vitro bactericidal activity against Gram-positive and Gram-negative bacteria. Amoxicillin is, however, susceptible to degradation by beta-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate some beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated beta-lactamases frequently responsible for transferred drug resistance. The formulation of amoxicillin and clavulanic acid in Amoxicillin and Clavulanate Potassium protects amoxicillin from degradation by some beta-lactamase enzymes and extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin. Amoxicillin and clavulanic acid has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections [see Indications and Usage ( 1 )] . Gram-positive bacteria Staphylococcus aureus Gram-negative bacteria Enterobacter species Escherichia coli Haemophilus influenzae Klebsiella species Moraxella catarrhalis The following in vitro data are available, but their clinical significance is unknown . At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for amoxicillin and clavulanic acid. However, the efficacy of amoxicillin and clavulanic acid in treating clinical infections due to these bacteria has not been established in adequate and well-controlled clinical trials. Gram-positive bacteria Enterococcus faecalis Staphylococcus epidermidis Staphylococcus saprophyticus Streptococcus pneumoniae Streptococcus pyogenes Viridans group Streptococcus Gram-negative Bacteria Eikenella corrodens Proteus mirabilis Anaerobic Bacteria Bacteroides species including Bacteroides fragilis Fusobacterium species Peptostreptococcus species Susceptibility Test Methods For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC ."],"indications_and_usage":["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, Amoxicillin and Clavulanate Potassium should not be used. ( 1 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium and other antibacterial drugs, Amoxicillin and Clavulanate Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1 ) Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, Amoxicillin and Clavulanate Potassium should not be used. Usage To reduce the development of drug‑resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium and other antibacterial drugs, Amoxicillin and Clavulanate Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Serious (including fatal) hypersensitivity reactions: Discontinue Amoxicillin and Clavulanate Potassium if a reaction occurs. ( 5.1 ) Severe Cutaneous Adverse Reactions (SCAR): Monitor closely. Discontinue if rash progresses. ( 5.2 ) Hepatic dysfunction and cholestatic jaundice: Discontinue if signs/symptoms of hepatitis occur. Monitor liver function tests in patients with hepatic impairment. ( 5.3 ) Clostridioides difficile -associated diarrhea (CDAD): Evaluate patients if diarrhea occurs. ( 5.4 ) Patients with mononucleosis who receive Amoxicillin and Clavulanate Potassium develop skin rash. Avoid Amoxicillin and Clavulanate Potassium use in these patients. ( 5.5 ) Overgrowth: The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. ( 5.6 ) 5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterials, including Amoxicillin and Clavulanate Potassium. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. Before initiating therapy with Amoxicillin and Clavulanate Potassium, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, Amoxicillin and Clavulanate Potassium should be discontinued, and appropriate therapy instituted. 5.2 Severe Cutaneous Adverse Reactions Amoxicillin and Clavulanate Potassium may cause severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If patients develop a skin rash, they should be monitored closely, and Amoxicillin and Clavulanate Potassium discontinued if lesions progress. 5.3 Hepatic Dysfunction Hepatic dysfunction, including hepatitis and cholestatic jaundice has been associated with the use of Amoxicillin and Clavulanate Potassium. Hepatic toxicity is usually reversible; however, deaths have been reported. Hepatic function should be monitored at regular intervals in patients with hepatic impairment. 5.4 Clostridioides difficile Associated Diarrhea (CDAD) Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Amoxicillin and Clavulanate Potassium, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. 5.5 Skin Rash in Patients with Mononucleosis A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash. Thus, Amoxicillin and Clavulanate Potassium should not be administered to patients with mononucleosis. 5.6 Potential for Microbial Overgrowth The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. If superinfection occurs, amoxicillin and clavulanate potassium should be discontinued and appropriate therapy instituted. 5.7 Phenylketonurics Amoxicillin and Clavulanate Potassium Chewable tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension contain aspartame which contains phenylalanine. Each 200 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 2.1 mg phenylalanine; each 400 mg chewable tablet contains 4.2 mg phenylalanine; each 5 mL of either the 200 mg/5 mL or 400 mg/5 mL oral suspension contains 7 mg phenylalanine. The other formulations of Amoxicillin and Clavulanate Potassium do not contain phenylalanine. 5.8 Development of Drug-Resistant Bacteria Prescribing Amoxicillin and Clavulanate Potassium in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug‑resistant bacteria."],"clinical_studies_table":["
Time Post Therapy875 mg every 12 hours % (n)500 mg every 8 hours % (n)
2 to 4 days81% (58)80% (54)
5 to 9 days58% (41)52% (52)
2 to 4 weeks 52% (101) 55% (104)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals have not been performed to evaluate carcinogenic potential. Amoxicillin and Clavulanate Potassium (4:1 ratio formulation of amoxicillin:clavulanate) was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and Clavulanate Potassium was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Amoxicillin and Clavulanate Potassium was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses of up to 1,200 mg/kg/day was found to have no effect on fertility and reproductive performance in rats. Based on body surface area, this dose of amoxicillin is approximately 4 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, the dose multiple is approximately 9 times higher than the maximum recommended adult human oral dose (125 mg every 8 hours), also based on body surface area."],"pharmacokinetics_table":["
a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5 hours after the dose.
b Amoxicillin and clavulanate potassium administered at the start of a light meal.
Dose and Regimen of Amoxicillin and ClavulanateCmax (mcg/mL)AUC0-24 (mcg*h/mL)
Amoxicillin and Clavulanate potassiumAmoxicillinClavulanate potassiumAmoxicillinClavulanate potassium
250 mg/125 mg every 8 hours 3.3 ± 1.121.5 ± 0.7026.7 ± 4.5612.6 ± 3.25
500 mg/125 mg every 12 hours 6.5 ± 1.411.8 ± 0.6133.4 ± 6.76 8.6 ± 1.95
500 mg/125 mg every 8 hours 7.2 ± 2.262.4 ± 0.8353.4 ± 8.8715.7 ± 3.86
875 mg/125 mg every 12 hours11.6 ± 2.782.2 ± 0.99 53.5 ± 12.3110.2 ± 3.04
","
Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parametersa,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets
a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose.
b Amoxicillin and clavulanate potassium administered at the start of a light meal.
Dose of Amoxicillin and ClavulanateCmax (mcg/mL)AUC0-24 (mcg*h/mL)
Amoxicillin and Clavulanate potassiumAmoxicillinClavulanate potassiumAmoxicillinClavulanate potassium
400 mg/57 mg (5 mL of suspension)6.94 ± 1.241.10 ± 0.4217.29 ± 2.282.34 ± 0.94
400 mg/57 mg (1 chewable tablet)6.67 ± 1.371.03 ± 0.3317.24 ± 2.642.17 ± 0.73
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Administration Instructions Inform patients that Amoxicillin and Clavulanate Potassium may be taken every 8 hours or every 12 hours, depending on the dose prescribed. Each dose should be taken with a meal or snack to reduce the possibility of gastrointestinal upset. Allergic Reactions Counsel patients that Amoxicillin and Clavulanate Potassium contains a penicillin class drug product that can cause allergic reactions in some individuals. Severe Cutaneous Adverse Reactions (SCAR ) Advise patients about the signs and symptoms of serious skin manifestations. Instruct patients to stop taking Amoxicillin and Clavulanate Potassium immediately and promptly report the first signs or symptoms of skin rash, mucosal lesions, or any other sign of hypersensitivity [see Warnings and Precautions ( 5.2 )] . Diarrhea Counsel patients that diarrhea is a common problem caused by antibacterials, and it usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibacterial. If diarrhea is severe or lasts more than 2 or 3 days, patients should contact their physician as soon as possible. Antibacterial Resistance Patients should be counseled that antibacterial drugs, including Amoxicillin and Clavulanate Potassium, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Amoxicillin and Clavulanate Potassium is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Amoxicillin and Clavulanate Potassium or other antibacterial drugs in the future. Storage Instructions Advise patients to keep suspension refrigerated. Shake well before using. When dosing a child with the suspension (liquid) of Amoxicillin and Clavulanate Potassium, use a calibrated oral syringe. Be sure to rinse the calibrated oral syringe after each use. Bottles of suspension of Amoxicillin and Clavulanate Potassium may contain more liquid than required. Follow your doctor's instructions about the amount to use and the days of treatment your child requires. Discard any unused medicine. Manufactured By: USAntibiotics, LLC Bristol, TN 37620 (USA) AUGMENTIN is a registered trademark of GlaxoSmithKline and is licensed to USAntibiotics, LLC. CLINITEST is a registered trademark of Miles, Inc."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Adults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on the amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 ) 2.1 Important Administration Instructions Amoxicillin and Clavulanate Potassium may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and Clavulanate Potassium is administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, Amoxicillin and Clavulanate Potassium should be taken at the start of a meal. 2.2 Adult Patients See dosing regimens of Amoxicillin and Clavulanate Potassium (based on the amoxicillin component) provided in Table 1 below. Table 1. Dosing Regimens of Amoxicillin and Clavulanate Potassium in Adult Patients TYPE OF INFECTION DOSING REGIMEN OF Amoxicillin and Clavulanate Potassium Severe infections and infections of the respiratory tract one 875 mg tablet a of Amoxicillin and Clavulanate Potassium every 12 hours or one 500 mg tablet b,c of Amoxicillin and Clavulanate Potassium every 8 hours Less severe infections one 500 mg tablet b,c of Amoxicillin and Clavulanate Potassium every 12 hours or one 250 mg tablet d of Amoxicillin and Clavulanate Potassium every 8 hours a Adults who have difficulty swallowing may be given the Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL suspension or the Amoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL suspension may be used in place of the 875 mg/125 mg tablet. b Adults who have difficulty swallowing may be given the Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL or Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg per 5 mL suspension in place of the 500 mg/125 mg tablet. c Two Amoxicillin and Clavulanate Potassium 250 mg/125 mg tablets are NOT substitutable with one 500 mg/125 mg Amoxicillin and Clavulanate Potassium tablet [see Dosage and Administration ( 2.6 )] . d Amoxicillin and Clavulanate Potassium 250 mg/125 mg tablet is NOT substitutable with Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg chewable tablet [see Dosage and Administration ( 2.6 )] 2.3 Pediatric Patients Based on the amoxicillin component, Amoxicillin and Clavulanate Potassium should be dosed as follows: Neonates and Infants Aged less than 12 weeks (less than 3 months) : See dosing regimens of Amoxicillin and Clavulanate Potassium provided in Table 2 below. Table 2: Dosing Regimens of Amoxicillin and Clavulanate Potassium in Neonates and Infants Aged Less than 12 Weeks (Less than 3 Months) PATIENT POPULATION DOSING REGIMEN Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL for oral suspension a Neonates and Infants aged less than 12 weeks (less than 3 months) 30 mg/kg/day every 12 hours a Experience with the Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL formulation in this age group is limited, and thus, use of the Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL for oral suspension is recommended. Patients Aged 12 weeks (3 months) and Older and Weighing Less than 40 kg : See dosing regimens provided in Table 3 below. The every 12 hour regimen is recommended as it is associated with significantly less diarrhea [see Clinical Studies ( 14.2 )] . The Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL and Amoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL) for oral suspension and Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg and Amoxicillin and Clavulanate Potassium 400 mg/57 mg chewable tablets contain aspartame and should not be used by phenylketonurics. [see Warnings and Precautions ( 5.7 )]. Table 3: Dosing in Patients Aged 12 Weeks (3 Months) and Older and Weighing Less than 40 kg a Each strength of Amoxicillin and Clavulanate Potassium oral suspension is available as a chewable tablet for use by older children. b Duration of therapy studied and recommended for acute otitis media is 10 days. INFECTION DOSING REGIMEN Every 12 hours Every 8 hours Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL or Amoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL oral suspension a Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL or Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg per 5 mL oral suspension a Otitis media b , sinusitis, lower respiratory tract infections, and more severe infections 45 mg/kg/day every 12 hours 40 mg/kg/day every 8 hours Less severe infections 25 mg/kg/day every 12 hours 20 mg/kg/day every 8 hours Patients Weighing 40 kg or More : Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations. The 250 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium should NOT be used until the child weighs at least 40 kg, due to the different amoxicillin to clavulanic acid ratios in the 250 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium versus the 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium. 2.4 Patients with Renal Impairment Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Renal impairment patients with a glomerular filtration rate (GFR) of less than 30 mL/min should NOT receive the 875 mg dose (based on the amoxicillin component) of Amoxicillin and Clavulanate Potassium. See dosing regimens in patients with severe renal impairment provided in Table 4. Table 4. Dosing Regimens of Amoxicillin and Clavulanate Potassium in Patients with Severe Renal Impairment Patients with Renal Impairment Dosing Regimen GFR 10 mL/min to 30 mL/min 500 mg or 250 mg every 12 hours, depending on the severity of the infection GFR less than 10 mL/min 500 mg or 250 mg every 24 hours, depending on severity of the infection Hemodialysis 500 mg or 250 mg every 24 hours, depending on severity of the infection Administer an additional dose both during and at the end of dialysis 2.5 Directions for Mixing Amoxicillin and Clavulanate Potassium for Oral Suspension Prepare Amoxicillin and Clavulanate Potassium for oral suspension at time of dispensing as follows: Tap bottle until all powder flows freely. Measure a total (see Table 5 below for total amount of water for reconstitution) OF WATER. Add approximately 2/3 of the water to the powder. Replace cap and shake VIGOROUSLY. Add remaining water. Replace cap and shake VIGOROUSLY. Table 5: Amount of Water for Mixing Amoxicillin and Clavulanate Potassium for Oral Suspension Strength of Amoxicillin and Clavulanate Potassiumfor Oral Suspension Bottle Size Amount of Water for Reconstitution Contents of Each Teaspoonful (5 mL) 125 mg/31.25 mg per 5 mL 75 mL 100 mL 150 mL 67 mL 90 mL 134 mL 125 mg of amoxicillin and 31.25 mg of clavulanic acid as the potassium salt 200 mg/28.5 mg per 5 mL 50 mL 75 mL 100 mL 50 mL 75 mL 95 mL 200 mg of amoxicillin and 28.5 mg of clavulanic acid as the potassium salt 250 mg/62.5 mg per 5 mL 75 mL 100 mL 150 mL 65 mL 87 mL 130 mL 250 mg of amoxicillin and 62.5 mg of clavulanic acid as the potassium salt 400 mg/57 mg per 5 mL 50 mL 75 mL 100 mL 50 mL 70 mL 90 mL 400 mg of amoxicillin and 57 mg of clavulanic acid as the potassium salt Shake oral suspension well before using. Reconstituted suspension must be stored under refrigeration and discarded after 10 days. Some color change is normal during dosing period. 2.6 Switching between Dosage Forms and between Strengths Amoxicillin and Clavulanate Potassium 250 mg/125 mg Tablet is NOT Substitutable with Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg Chewable Tablet The 250 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium and the 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium should NOT be substituted for each other and the 250 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium should NOT be used in pediatric patients weighing less than 40 kg [see Dosage and Administration ( 2.3 )] . The 250 mg tablet of Amoxicillin and Clavulanate Potassium and the 250 mg chewable tablet of Amoxicillin and Clavulanate Potassium do not contain the same amount of clavulanic acid. The 250 mg tablet of Amoxicillin and Clavulanate Potassium contains 125 mg of clavulanic acid whereas the 250 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 62.5 mg of clavulanic acid. Two Amoxicillin and Clavulanate Potassium 250 mg/125 mg Tablets are NOT Substitutable with One 500 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet Two 250 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium should NOT be substituted for one 500 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium. Since both the 250 mg and 500 mg tablets of Amoxicillin and Clavulanate Potassium contain the same amount of clavulanic acid (125 mg, as the potassium salt), two 250 mg tablets of Amoxicillin and Clavulanate Potassium are not equivalent to one 500 mg tablet of Amoxicillin and Clavulanate Potassium."],"spl_product_data_elements":["AMOXICILLIN AND CLAVULANATE POTASSIUM amoxicillin and clavulanate potassium AMOXICILLIN AMOXICILLIN ANHYDROUS CLAVULANATE POTASSIUM CLAVULANIC ACID SILICON DIOXIDE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED white capsule AUGMENTIN;875"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Amoxicillin and Clavulanate Potassium Tabl ets, USP : 250 mg/125 mg Tablets: Each white oval film-coated tablet, debossed with AUGMENTIN on one side and 250/125 on the other side, contains 250 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt. 500 mg/125 mg Tablets : Each white oval film-coated tablet, debossed with AUGMENTIN on one side and 500/125 on the other side, contains 500 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt. 875 mg/125 mg Tablets : Each scored white capsule‑shaped tablet, debossed with AUGMENTIN 875 on one side and scored on the other side, contains 875 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt. Amoxicillin and Clavulanate Potassium for Oral Suspension, USP: 125 mg/31.25 mg per 5 mL : Banana-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 125 mg of amoxicillin as the trihydrate and 31.25 mg of clavulanic acid as the potassium salt). 200 mg/28.5 mg per 5 mL : Orange-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 200 mg of amoxicillin as the trihydrate and 28.5 mg of clavulanic acid as the potassium salt). 250 mg/62.5 mg per 5 mL : Orange-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 250 mg of amoxicillin as the trihydrate and 62.5 mg of clavulanic acid as the potassium salt). 400 mg/57 mg per 5 mL: Orange-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 400 mg of amoxicillin as the trihydrate and 57 mg of clavulanic acid as the potassium salt). Amoxicillin and Clavulanate Potassium Chewable Tablets, USP: 125 mg/31.25 mg Chewable Tablets : Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 189 contains 125 mg of amoxicillin as the trihydrate and 31.25 mg of clavulanic acid as the potassium salt. 200 mg/28.5 mg Chewable Tablets : Each mottled pink, round, biconvex cherry-banana-flavored tablet, debossed with AUGMENTIN 200 contains 200 mg of amoxicillin as the trihydrate and 28.5 mg of clavulanic acid as the potassium salt. 250 mg/62.5 mg Chewable Tablets : Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 190 contains 250 mg of amoxicillin as the trihydrate and 62.5 mg of clavulanic acid as the potassium salt. 400 mg/57 mg Chewable Tablets : Each mottled pink, round, biconvex cherry-banana-flavored tablet, debossed with AUGMENTIN 400 contains 400 mg of amoxicillin as the trihydrate and 57 of clavulanic acid as the potassium salt. Tablets: 250 mg/125 mg, 500 mg/125 mg, 875 mg/125 mg; 875 mg/125 mg tablets are scored. ( 3 ) For Oral Suspension: 125 mg/31.25 mg per 5 mL, 200 mg/28.5 mg per 5 mL, 250 mg/62.5 mg per 5 mL, 400 mg/57 mg per 5 mL ( 3 ) Chewable Tablets: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg, 400 mg/57 mg ( 3 )"],"recent_major_changes_table":["
Warnings and Precautions (5)8/2022
"],"clinical_pharmacology_table":["
a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5 hours after the dose.
b Amoxicillin and clavulanate potassium administered at the start of a light meal.
Dose and Regimen of Amoxicillin and ClavulanateCmax (mcg/mL)AUC0-24 (mcg*h/mL)
Amoxicillin and Clavulanate potassiumAmoxicillinClavulanate potassiumAmoxicillinClavulanate potassium
250 mg/125 mg every 8 hours 3.3 ± 1.121.5 ± 0.7026.7 ± 4.5612.6 ± 3.25
500 mg/125 mg every 12 hours 6.5 ± 1.411.8 ± 0.6133.4 ± 6.76 8.6 ± 1.95
500 mg/125 mg every 8 hours 7.2 ± 2.262.4 ± 0.8353.4 ± 8.8715.7 ± 3.86
875 mg/125 mg every 12 hours11.6 ± 2.782.2 ± 0.99 53.5 ± 12.3110.2 ± 3.04
","
Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parametersa,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets
a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose.
b Amoxicillin and clavulanate potassium administered at the start of a light meal.
Dose of Amoxicillin and ClavulanateCmax (mcg/mL)AUC0-24 (mcg*h/mL)
Amoxicillin and Clavulanate potassiumAmoxicillinClavulanate potassiumAmoxicillinClavulanate potassium
400 mg/57 mg (5 mL of suspension)6.94 ± 1.241.10 ± 0.4217.29 ± 2.282.34 ± 0.94
400 mg/57 mg (1 chewable tablet)6.67 ± 1.371.03 ± 0.3317.24 ± 2.642.17 ± 0.73
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pediatric Use: Modify dose in patients 12 weeks or younger. ( 8.4 ) Renal Impairment: Dosage adjustment is recommended for severe renal impairment (GFR less than 30mL/min). ( 2.4 , 8.6 ) Revised 03/2024 8.1 Pregnancy Teratogenic Effects : Pregnancy Category B. Reproduction studies performed in pregnant rats and mice given Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to Amoxicillin and Clavulanate Potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. 8.2 Labor and Delivery Oral ampicillin‑class antibacterials are poorly absorbed during labor. It is not known whether use of amoxicillin and clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention. 8.3 Nursing Mothers Amoxicillin has been shown to be excreted in human milk. Amoxicillin and clavulanate potassium use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman. 8.4 Pediatric Use The safety and effectiveness of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets have been established in pediatric patients. Use of Amoxicillin and Clavulanate Potassium in pediatric patients is supported by evidence from studies of Amoxicillin and Clavulanate Potassium Tablets in adults with additional data from a study of Amoxicillin and Clavulanate Potassium for Oral Suspension in pediatric patients aged 2 months to 12 years with acute otitis media [see Clinical Studies ( 14.2 )] . Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group. Dosing of Amoxicillin and Clavulanate Potassium should be modified in pediatric patients aged less than 12 weeks (less than 3 months) [see Dosage and Administration ( 2.3 )]. 8.5 Geriatric Use Of the 3,119 patients in an analysis of clinical studies of Amoxicillin and Clavulanate Potassium, 32% were greater than or equal to 65 years old, and 14% were greater than or equal to 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. 8.6 Renal Impairment Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (GFR less than 30 mL/min). See Patients with Renal Impairment [see Dosage and Administration ( 2.4 )] for specific recommendations in patients with renal impairment."],"dosage_and_administration_table":["
TYPE OF INFECTIONDOSING REGIMEN OF Amoxicillin and Clavulanate Potassium
Severe infections and infections of the respiratory tractone 875 mg tableta of Amoxicillin and Clavulanate Potassium every 12 hours or one 500 mg tabletb,c of Amoxicillin and Clavulanate Potassium every 8 hours
Less severe infections one 500 mg tabletb,c of Amoxicillin and Clavulanate Potassium every 12 hours or one 250 mg tabletd of Amoxicillin and Clavulanate Potassium every 8 hours
","
PATIENT POPULATIONDOSING REGIMEN
Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL for oral suspensiona
Neonates and Infants aged less than 12weeks (less than 3 months) 30 mg/kg/day every 12 hours
","
a Each strength of Amoxicillin and Clavulanate Potassium oral suspension is available as a chewable tablet for use by older children.
b Duration of therapy studied and recommended for acute otitis media is 10 days.
INFECTIONDOSING REGIMEN
Every 12 hoursEvery 8 hours
Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL orAmoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL oral suspensionaAmoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL orAmoxicillin and Clavulanate Potassium 250 mg/62.5 mg per 5 mL oral suspensiona
Otitis mediab, sinusitis, lower respiratory tract infections, and more severe infections45 mg/kg/day every 12 hours40 mg/kg/day every 8 hours
Less severe infections25 mg/kg/day every 12 hours20 mg/kg/day every 8 hours
","
Patients with Renal ImpairmentDosing Regimen
GFR 10 mL/min to 30 mL/min 500 mg or 250 mg every 12 hours, dependingon the severity of the infection
GFR less than 10 mL/min 500 mg or 250 mg every 24 hours, dependingon severity of the infection
Hemodialysis 500 mg or 250 mg every 24 hours, dependingon severity of the infection Administer an additional dose both duringand at the end of dialysis
","
Strength of Amoxicillin and Clavulanate Potassiumfor Oral SuspensionBottle SizeAmount of Water for ReconstitutionContents of Each Teaspoonful (5 mL)
125 mg/31.25 mgper 5 mL75 mL 100 mL 150 mL 67 mL 90 mL 134 mL125 mg of amoxicillin and 31.25 mg of clavulanic acid as the potassium salt
200 mg/28.5 mgper 5 mL50 mL 75 mL 100 mL 50 mL 75 mL 95 mL200 mg of amoxicillin and 28.5 mg of clavulanic acid as the potassium salt
250 mg/62.5 mgper 5 mL75 mL 100 mL 150 mL 65 mL 87 mL 130 mL250 mg of amoxicillin and 62.5 mg of clavulanic acid as the potassium salt
400 mg/57 mgper 5 mL50 mL 75 mL 100 mL 50 mL 70 mL 90 mL400 mg of amoxicillin and 57 mg of clavulanic acid as the potassium salt
"],"package_label_principal_display_panel":["AMOXICILLIN AND CLAVULANATE POTASSIUM Label Image"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals have not been performed to evaluate carcinogenic potential. Amoxicillin and Clavulanate Potassium (4:1 ratio formulation of amoxicillin:clavulanate) was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and Clavulanate Potassium was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Amoxicillin and Clavulanate Potassium was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses of up to 1,200 mg/kg/day was found to have no effect on fertility and reproductive performance in rats. Based on body surface area, this dose of amoxicillin is approximately 4 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, the dose multiple is approximately 9 times higher than the maximum recommended adult human oral dose (125 mg every 8 hours), also based on body surface area."]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"5823 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"5410 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"5017 reports"},{"date":"","signal":"CHRONIC KIDNEY DISEASE","source":"FDA FAERS","actionTaken":"4929 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"4898 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"4860 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"4499 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"4418 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"4390 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"3968 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Diarrhea/loose stools","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Skin rashes and urticaria","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Vaginitis","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Abdominal discomfort","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"0.5%","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Cholestatic hepatitis","Disease of liver","Fracture of bone","Hepatic failure","Hypomagnesemia","Infectious mononucleosis","Kidney disease","Liver function tests abnormal","Myasthenia gravis","Obstruction of bile duct","Osteoporosis","Porphyria","Prolonged QT interval","Pseudomembranous enterocolitis","Torsades de pointes","Ventricular tachycardia"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Anaphylactic/anaphylactoid reactions (including shock)","drugRate":"","severity":"serious"},{"effect":"Stevens-Johnson Syndrome (SJS)","drugRate":"","severity":"serious"},{"effect":"Toxic Epidermal Necrolysis (TEN)","drugRate":"","severity":"serious"},{"effect":"Pseudomembranous colitis","drugRate":"","severity":"serious"},{"effect":"Hepatitis and cholestatic jaundice","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Serum sickness-like reactions","drugRate":"","severity":"serious"},{"effect":"Drug-induced enterocolitis syndrome (DIES)","drugRate":"","severity":"serious"},{"effect":"Hypersensitivity vasculitis","drugRate":"","severity":"serious"},{"effect":"DRESS syndrome","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT05142891","NCT04034641","NCT01450241","NCT01434173","NCT06751121","NCT02547025","NCT00801099","NCT01967329","NCT01818336","NCT01219764","NCT02927834","NCT03779087","NCT04047849","NCT04178187","NCT01205984","NCT04268407","NCT01156740","NCT01951768","NCT02197260","NCT01431989","NCT02988089","NCT05870397","NCT05079620","NCT04378231","NCT01980095","NCT02175901","NCT05749081","NCT05002595","NCT02381470","NCT00644553","NCT03625739","NCT05361499","NCT03198507","NCT00778544","NCT05449028","NCT03412305","NCT04534426","NCT03134378","NCT00840840","NCT07104318","NCT01906879","NCT01166932","NCT06811207","NCT03908619","NCT06055257","NCT02368470","NCT00643539","NCT02514941","NCT02761005","NCT02899702"],"aliases":["Amoxil","Trimox","Moxatag"],"patents":[{"type":"Method of Use","number":"8299052","applicant":"PRAGMA PHARMACEUTICALS LLC","territory":"US","tradeName":"MOXATAG","expiryDate":"2027-05-07"},{"type":"Compound","number":"8778924","applicant":"PRAGMA PHARMACEUTICALS LLC","territory":"US","tradeName":"MOXATAG","expiryDate":"2026-12-08"},{"type":"Formulation","number":"8357394","applicant":"PRAGMA PHARMACEUTICALS LLC","territory":"US","tradeName":"MOXATAG","expiryDate":"2026-12-08"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0190/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$7","description":"AMOXICILLIN 125 MG/5 ML SUSP","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=amoxicillin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:08:40.867469+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:08:40.866370+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:08:46.498780+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:08:39.983882+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=amoxicillin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:08:46.786150+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:08:32.806899+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:08:32.806935+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:08:48.305101+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105950/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:08:47.486622+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA050720","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:08:32.806939+00:00"}},"allNames":"amoxil","offLabel":[],"timeline":[],"brandName":"Amoxil","companyId":"unknown","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","novelty":"","modality":"Small molecule","drugClass":"Aminopenicillin (Beta-lactam antibiotic)","explanation":"Amoxicillin is the most prescribed antibiotic worldwide, developed as an improved version of ampicillin with better oral absorption and broader spectrum. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. It is the first-line antibiotic for many common infections including otitis media, sinusitis, and streptococcal pharyngitis.","oneSentence":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins.","technicalDetail":"","_target_confidence":0.5},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:51.307228+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"companyName":"Generic (originally Beecham/GSK)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"amoxicillin","indications":{"approved":[{"name":"Acute bacterial sinusitis","diseaseId":"acute-bacterial-sinusitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute exacerbation of chronic bronchitis","diseaseId":"acute-exacerbation-of-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute otitis media","diseaseId":"acute-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial pneumonia","diseaseId":"bacterial-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial urinary infection","diseaseId":"bacterial-urinary-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Duodenal Ulcer due to H. Pylori","diseaseId":"duodenal-ulcer-due-to-h.-pylori","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Genitourinary Tract Infection","diseaseId":"e.-coli-genitourinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Enterococcus Genitourinary Tract Infection","diseaseId":"enterococcus-genitourinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Escherichia coli urinary tract infection","diseaseId":"escherichia-coli-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Genitourinary Tract Infection due to Proteus","diseaseId":"genitourinary-tract-infection-due-to-proteus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Genitourinary Tract Infections","diseaseId":"genitourinary-tract-infections","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus Influenzae Acute Otitis Media","diseaseId":"haemophilus-influenzae-acute-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus Influenzae Chronic Bronchitis","diseaseId":"haemophilus-influenzae-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus Influenzae Pharyngitis","diseaseId":"haemophilus-influenzae-pharyngitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus Parainfluenzae Pneumonia","diseaseId":"haemophilus-parainfluenzae-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus influenzae pneumonia","diseaseId":"haemophilus-influenzae-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection caused by Helicobacter pylori","diseaseId":"infection-caused-by-helicobacter-pylori","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Escherichia coli","diseaseId":"infection-due-to-escherichia-coli","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Staphylococcus aureus","diseaseId":"infection-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection of skin AND/OR subcutaneous tissue","diseaseId":"infection-of-skin-and/or-subcutaneous-tissue","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infective otitis media","diseaseId":"infective-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella cystitis","diseaseId":"klebsiella-cystitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lower respiratory tract infection","diseaseId":"lower-respiratory-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Moraxella Catarrhalis Acute Otitis Media","diseaseId":"moraxella-catarrhalis-acute-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Moraxella Catarrhalis Pneumonia","diseaseId":"moraxella-catarrhalis-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pharyngitis","diseaseId":"pharyngitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumococcal Acute Otitis Media","diseaseId":"pneumococcal-acute-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumococcal pneumonia","diseaseId":"pneumococcal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Klebsiella pneumoniae","diseaseId":"pneumonia-due-to-klebsiella-pneumoniae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Staphylococcus aureus","diseaseId":"pneumonia-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Streptococcus","diseaseId":"pneumonia-due-to-streptococcus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rhinoscleroma","diseaseId":"rhinoscleroma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Skin and Skin Structure Streptococcus Infection","diseaseId":"skin-and-skin-structure-streptococcus-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal pharyngitis","diseaseId":"staphylococcal-pharyngitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal tonsillitis","diseaseId":"staphylococcal-tonsillitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Streptococcal tonsillitis","diseaseId":"streptococcal-tonsillitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Streptococcus Pneumoniae Chronic Bronchitis","diseaseId":"streptococcus-pneumoniae-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Streptococcus pyogenes infection","diseaseId":"streptococcus-pyogenes-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tonsillitis due to Haemophilus Influenzae","diseaseId":"tonsillitis-due-to-haemophilus-influenzae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urinary tract infectious disease","diseaseId":"urinary-tract-infectious-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05142891","phase":"N/A","title":"Incidence of Actue Kidney Injury in Patients Treated With Amoxicillin and Cloxacillin Combination Therapy","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","isPivotal":false,"enrollment":50,"indication":"Endocarditis, Acute Kidney Injury","completionDate":"2022-10-30"},{"nctId":"NCT04034641","phase":"Phase 4","title":"Clinical Study on Bifidobacterium Quadruple Live Bacteria Tablets (Si Lian Kang) Reducing the Incidence Rate of Adverse Reactions in Helicobacter Pylori Quadruple Eradication Therapy and on the Effect","status":"UNKNOWN","sponsor":"Hangzhou Grand Biologic Pharmaceutical, Inc.","isPivotal":false,"enrollment":238,"indication":"Helicobacter Pylori Eradication","completionDate":"2021-12-31"},{"nctId":"NCT01450241","phase":"NA","title":"Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia: Randomized-controlled Trial","status":"WITHDRAWN","sponsor":"Rabin Medical Center","isPivotal":false,"enrollment":0,"indication":"Febrile Neutropenia","completionDate":"2015-01"},{"nctId":"NCT01434173","phase":"N/A","title":"Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":1299056,"indication":"Drug-Induced Liver Injury","completionDate":"2009-03"},{"nctId":"NCT06751121","phase":"Phase 3","title":"A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacte","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","isPivotal":true,"enrollment":461,"indication":"Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients","completionDate":"2025-04-24"},{"nctId":"NCT02547025","phase":"NA","title":"Personalized Treatment for Refractory H Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","isPivotal":false,"enrollment":126,"indication":"Helicobacter Pylori Infection","completionDate":"2021-10-31"},{"nctId":"NCT00801099","phase":"NA","title":"Benefit of a Single Preoperative Dose of Antibiotics in a Sub-Saharan District Hospital: Minimal Input, Massive Impact","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","isPivotal":false,"enrollment":276,"indication":"Surgical Site Infection","completionDate":"2005-03"},{"nctId":"NCT01967329","phase":"Phase 4","title":"Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials","status":"COMPLETED","sponsor":"University of Alberta","isPivotal":false,"enrollment":338,"indication":"Helicobacter Pylori Infection","completionDate":"2019-05"},{"nctId":"NCT01818336","phase":"Phase 3","title":"Confirmatory Study to Examine Negative Predictive Value (NPV) and Safety of Skin Testing With PRE-PEN, a Minor Determinant MIxture (MDM) of Penicillin Antigens, and Amoxicillin Reagent Against an Oral","status":"COMPLETED","sponsor":"AllerQuest LLC","isPivotal":true,"enrollment":481,"indication":"History of IgE Dependent Reaction to a Penicillin Product","completionDate":"2013-06"},{"nctId":"NCT01219764","phase":"Phase 4","title":"A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","isPivotal":false,"enrollment":200,"indication":"Helicobacter Infections","completionDate":"2013-03"},{"nctId":"NCT02927834","phase":"NA","title":"The Role of Oral Steroids in the Management of Chronic Rhinosinusitis Without Nasal Polyps","status":"COMPLETED","sponsor":"Loma Linda University","isPivotal":false,"enrollment":24,"indication":"Sinusitis","completionDate":"2019-01"},{"nctId":"NCT03779087","phase":"NA","title":"Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection - a Multi-center Randomized Controlled Trial","status":"COMPLETED","sponsor":"Ping-I (William) Hsu, M.D.","isPivotal":false,"enrollment":112,"indication":"Helicobacter Pylori Infection","completionDate":"2020-06-30"},{"nctId":"NCT04047849","phase":"Phase 4","title":"The Effect of Antibiotics on Latency in Previable Prelabor Rupture of Membranes Between 18 0/7 and 22 6/7 Weeks Gestational Age","status":"RECRUITING","sponsor":"Woman's","isPivotal":false,"enrollment":34,"indication":"Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture), Rupture of Membranes; Premature","completionDate":"2021-07-01"},{"nctId":"NCT04178187","phase":"NA","title":"The Role of Probiotics in the Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Evangelismos Hospital","isPivotal":false,"enrollment":660,"indication":"Helicobacter Pylori Infection","completionDate":"2021-12-31"},{"nctId":"NCT01205984","phase":"Phase 4","title":"Efficacy and Tolerability of Systemic Methylprednisolone in Children and Adolescents With Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","isPivotal":false,"enrollment":48,"indication":"Chronic Rhinosinusitis, Children","completionDate":"2010-04"},{"nctId":"NCT04268407","phase":"NA","title":"2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","isPivotal":false,"enrollment":60,"indication":"Thyroid Nodule","completionDate":"2021-12-31"},{"nctId":"NCT01156740","phase":"NA","title":"Treatment of Pharyngitis Study (TOPS): A Randomized Equivalence Trial of Intramuscular Penicillin G vs. Oral Amoxicillin Antibiotics for the Treatment of Streptococcal Pharyngitis in Children in Devel","status":"COMPLETED","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":558,"indication":"Streptococcal Infections, Pharyngitis","completionDate":"2003-04"},{"nctId":"NCT01951768","phase":"Phase 4","title":"A Randomized, Controlled Study to Investigate the Efficacy and Safety of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With a Moderate or Se","status":"COMPLETED","sponsor":"University Hospital, Geneva","isPivotal":false,"enrollment":88,"indication":"Diabetic Foot Ulcer","completionDate":"2016-06"},{"nctId":"NCT02197260","phase":"Phase 4","title":"Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing on Clinical, Microbiological and Systemic Response","status":"COMPLETED","sponsor":"University of Geneva, Switzerland","isPivotal":false,"enrollment":80,"indication":"Chronic Periodontitis","completionDate":"2014-03"},{"nctId":"NCT01431989","phase":"Phase 1","title":"Evaluation of Pharmaceutical Bioequivalence of Amoxicillin Trihydrate - Clamoxyl 500mg/5mL (Glaxo Wellcome Production.) in the Form Powder for Oral Suspension Versus Amoxil ® 500mg/5mL (GlaxoSmithKlin","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":28,"indication":"Infections, Bacterial","completionDate":"2011-06-11"},{"nctId":"NCT02988089","phase":"Phase 4","title":"Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Shandong University","isPivotal":false,"enrollment":480,"indication":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","completionDate":"2017-09"},{"nctId":"NCT05870397","phase":"NA","title":"Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective, Single-center, Open-label, Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":900,"indication":"Helicobacter Pylori Eradication","completionDate":"2024-08-21"},{"nctId":"NCT05079620","phase":"Phase 4","title":"Antibiotic Prophylaxis in Critically Ill Patients After Suspected Aspiration","status":"TERMINATED","sponsor":"UConn Health","isPivotal":false,"enrollment":5,"indication":"Aspiration, Aspiration Pneumonia","completionDate":"2024-04-12"},{"nctId":"NCT04378231","phase":"NA","title":"Higher Versus Standard Dose of Amoxicillin-clavulanate in Pediatric Protracted Bacterial Bronchitis: a Randomized Controlled Study.","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","isPivotal":false,"enrollment":100,"indication":"Protracted Bacterial Bronchitis","completionDate":"2022-07"},{"nctId":"NCT01980095","phase":"Phase 3","title":"A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patient","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","isPivotal":true,"enrollment":119,"indication":"Dyspepsia, Helicobacter Pylori Infection","completionDate":"2015-08"},{"nctId":"NCT02175901","phase":"Phase 4","title":"Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line H","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","isPivotal":false,"enrollment":215,"indication":"Dyspepsia, Peptic Ulcer","completionDate":"2015-01"},{"nctId":"NCT05749081","phase":"Phase 4","title":"Lacidophilin Tablets in Combination With Vonorazan and Amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection: a Prospective, Multi-centers, Superiority, Double-blind, Randomized Clini","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Nanchang University","isPivotal":false,"enrollment":324,"indication":"Helicobacter Pylori Infection","completionDate":"2024-07"},{"nctId":"NCT05002595","phase":"N/A","title":"Comparison of Helicobacter Pylori Treatment Between Modified Quadruple Therapy and Tailored Eradication Based on the Presence of Clarithromycin Resistance","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","isPivotal":false,"enrollment":270,"indication":"H. Pylori Infection","completionDate":"2021-12-31"},{"nctId":"NCT02381470","phase":"Phase 2","title":"Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effect","status":"COMPLETED","sponsor":"National University Hospital, Singapore","isPivotal":false,"enrollment":58,"indication":"Pulmonary Tuberculosis","completionDate":"2019-10-02"},{"nctId":"NCT00644553","phase":"Phase 3","title":"A Phase IIIB/IV Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets vs. Amoxicillin-Clavulanate for the Treatment of Subjects With Acute Bacterial Sinusitis","status":"COMPLETED","sponsor":"Abbott","isPivotal":true,"enrollment":437,"indication":"Acute Bacterial Sinusitis (ABS)","completionDate":""},{"nctId":"NCT03625739","phase":"N/A","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","isPivotal":false,"enrollment":800,"indication":"Tuberculosis","completionDate":"2026-12-31"},{"nctId":"NCT05361499","phase":"NA","title":"A Controlled Human Pneumococcal Infection Model (PIM) Study","status":"COMPLETED","sponsor":"Radboud University Medical Center","isPivotal":false,"enrollment":20,"indication":"Streptococcus Pneumoniae Infection","completionDate":"2023-02-16"},{"nctId":"NCT03198507","phase":"Phase 3","title":"A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","isPivotal":true,"enrollment":455,"indication":"Helicobacter Pylori Infection, Dyspepsia","completionDate":"2018-12-13"},{"nctId":"NCT00778544","phase":"NA","title":"Randomized, Open-Label, 2 - Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg- 42.9 mg/ 5 mL Oral Suspension and Augmentin ES-600 (Reference) Following a 600 mg- 42.9 mg Dose i","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","isPivotal":false,"enrollment":48,"indication":"Healthy","completionDate":"2006-09"},{"nctId":"NCT05449028","phase":"NA","title":"Helicobacter Pylori Eradication Therapy in Portugal: Prospective, Randomized, Blind and Multicentre Trial on the Efficacy of Quadruple Therapies and Their Clinical Impact, and Immunological and Gut Mi","status":"UNKNOWN","sponsor":"Unidade Local de Saúde de Coimbra, EPE","isPivotal":false,"enrollment":230,"indication":"Helicobacter Pylori, Gut Microbiota","completionDate":"2024-12-31"},{"nctId":"NCT03412305","phase":"Phase 4","title":"Effect of Antibiotic Prophylaxis in Dental Implant Surgery - a Multicenter Placebo-controlled Double-blinded Randomized Clinical Trial","status":"COMPLETED","sponsor":"Malmö University","isPivotal":false,"enrollment":474,"indication":"Infection Control, Antibiotic Prophylaxis","completionDate":"2021-08-10"},{"nctId":"NCT04534426","phase":"Phase 4","title":"Influence of Different Topical Arnica and Mucopolysaccharide Polysulfate on Postoperative Pain, Edema and Trismus After Extraction of Impacted Third Molar","status":"COMPLETED","sponsor":"Abant Izzet Baysal University","isPivotal":false,"enrollment":60,"indication":"Impacted Third Molar Tooth","completionDate":"2020-01-30"},{"nctId":"NCT03134378","phase":"Phase 4","title":"Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Indonesia University","isPivotal":false,"enrollment":73,"indication":"Helicobacter Pylori Infection","completionDate":"2017-05-12"},{"nctId":"NCT00840840","phase":"Phase 1","title":"An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects, Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","isPivotal":false,"enrollment":48,"indication":"Healthy","completionDate":"2002-08"},{"nctId":"NCT07104318","phase":"Phase 3","title":"Randomized Clinical Trial of Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans: \"VA Eradicate HP\"","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","isPivotal":true,"enrollment":360,"indication":"Helicobacter Pylori","completionDate":"2030-03-31"},{"nctId":"NCT01906879","phase":"Phase 4","title":"Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":1620,"indication":"Helicobacter Pylori Infection","completionDate":"2017-12"},{"nctId":"NCT01166932","phase":"Phase 4","title":"COMPARISON OF CLINICAL EFFICACY OF COMBINATION Amoxycillin Plus Clavulanic Acid and Oxacillin Plus Ceftriaxone for HOSPITAL TREATMENT OF COMMUNITY Acquired PNEUMONIA IN CHILDREN : A Randomized Clinica","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","isPivotal":false,"enrollment":104,"indication":"Community-Acquired Pneumonia","completionDate":"2009-04"},{"nctId":"NCT06811207","phase":"Phase 3","title":"Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","isPivotal":true,"enrollment":300,"indication":"HELICOBACTER PYLORI INFECTIONS","completionDate":"2025-02-28"},{"nctId":"NCT03908619","phase":"Phase 4","title":"A Randomized Controlled Trial of Triple Therapy With Conventional Proton Pump Inhibitor vs Triple Therapy With Vonoprazan as First Line Therapy for Helicobacter Pylori Gastritis","status":"UNKNOWN","sponsor":"Changi General Hospital","isPivotal":false,"enrollment":252,"indication":"Helicobacter Pylori Infection","completionDate":"2021-03-31"},{"nctId":"NCT06055257","phase":"Phase 3","title":"Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible, a Pilot Randomized Control Trial","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","isPivotal":true,"enrollment":24,"indication":"Osteoradionecrosis, Osteoradionecrosis of Jaw","completionDate":"2027-12"},{"nctId":"NCT02368470","phase":"Phase 3","title":"Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Samsung Medical Center","isPivotal":true,"enrollment":252,"indication":"Helicobacter Pylori Infection","completionDate":"2015-10"},{"nctId":"NCT00643539","phase":"Phase 4","title":"Multicenter, Open, Randomized Comparative Trial To Compare Bacteriological And Clinical Efficacy Of Azithromycin Versus Amoxicillin In Children With Streptococcus Tonsillitis","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":360,"indication":"Tonsillitis","completionDate":"2003-07"},{"nctId":"NCT02514941","phase":"Phase 1","title":"Bioavailability of Paracetamol, Amoxicillin and Talinolol and Expression of Intestinal Drug Metabolizing Enzymes and Transport Proteins Before, Immediately and One Year After Proximal Roux-en-Y Gastri","status":"COMPLETED","sponsor":"University Medicine Greifswald","isPivotal":false,"enrollment":12,"indication":"Morbid Obesity","completionDate":""},{"nctId":"NCT02761005","phase":"Phase 2","title":"Eradication of H. Pylori With the Regimen Individualized Susceptibility of H. Pylori to Clarithromycin Determined by the Mutation of 23S rRNA of H. Pylori","status":"UNKNOWN","sponsor":"Hamamatsu University","isPivotal":false,"enrollment":100,"indication":"H. Pylori Infection","completionDate":"2018-05"},{"nctId":"NCT02899702","phase":"Phase 4","title":"Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children: a Multicentre European Randomized Controlled Trial","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","isPivotal":false,"enrollment":0,"indication":"Staphylococcal Infection, Streptococcal Infection","completionDate":"2024-09"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Two to three times daily","formulation":"Capsule, Tablet, Chewable tablet, Oral suspension"},"crossReferences":{"chemblId":"CHEMBL2105950"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":22548,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"firstApprovalDate":"1972-01-01","companionDiagnostics":[],"firstApprovalCountry":"United Kingdom","genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-02-28T00:00:00.000Z","mah":"TEVA","brand_name_local":null,"application_number":"ANDA064013"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-08-07T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":"ANDA064076"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-09-08T00:00:00.000Z","mah":"TEVA","brand_name_local":null,"application_number":"ANDA065162"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-08-27T00:00:00.000Z","mah":"US ANTIBIOTICS","brand_name_local":null,"application_number":"NDA050785"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-05-01T00:00:00.000Z","mah":"MICRO LABS LTD INDIA","brand_name_local":null,"application_number":"ANDA205707"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8778924","territory":"US","patent_type":"Compound","expiry_date":"2026-12-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8357394","territory":"US","patent_type":"Formulation","expiry_date":"2026-12-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8299052","territory":"US","patent_type":"Method of Use","expiry_date":"2027-05-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:51.307228+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}